Enhanced inhibitory effect on glioblastoma by combined use of CUDC-907 and temozolomide (TMZ). (IMAGE)
Caption
(A) 2D heatmaps show the percentage of cell viability after different doses of CUDC-907 and TMZ treatment in LN229 and A172. Cell viability was measured by the CCK8 assay after 48 h of drug treatment. The SynergyFinder Plus online tool was used for Bliss synergistic analysis to evaluate the synergistic effect of the combination treatment in LN229 and A172. (B) Incucyte cell confluence assays show the synergistic effect of the CUDC-907 and TMZ treatment on cell proliferation (% confluence) over time. (C) EdU positive LN229 and A172 cells after treatment with CUDC-907 and TMZ for 48 h. Scale bars = 50 μm. (D) Representative diagram of GBO with treatment of CUDC-907 and TMZ for 7 days. Scale bars = 500 μm. (E) EdU and Ki67 positive cells in GBO after treatment with CUDC-907 and TMZ for 7 days. Scale bars = 50 μm. The data were expressed as mean ± standard deviation. Student’s t-test was performed to analyze significance. ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001.
Credit
Chencheng Fang, Pan Gou, Dandan Zhang, Xuanxuan Wu, Xiao Li, Man Li, Lu Gan, Jinjin Luo, Hongjuan Cui, Man Xu, Ping Liang
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND